7 Drugs Approved for Primary Care: Q2 2026

The FDA approved several new or expanded treatment options during the second quarter of 2026 with direct implications for conditions commonly managed or identified in primary care, including obesity, hypertension, diabetes, acne, urinary tract infection, HIV-1 infection, and COVID-19 exposure. The approvals include first-in-class or first-in-category agents, new combination therapies, and options that may affect prescribing conversations, referral decisions, and patient counseling in routine clinical practice.